American Journal of Clinical Oncology-Cancer Clinical Trials最新文献

{"title":"AI Prognostication in Nonsmall Cell Lung Cancer: A Systematic Review.","authors":"Michael Augustin, Kelsey Lyons, Hayeon Kim, David G Kim, Yusung Kim","doi":"10.1097/COC.0000000000001238","DOIUrl":"https://doi.org/10.1097/COC.0000000000001238","url":null,"abstract":"<p><p>The systematic literature review was performed on the use of artificial intelligence (AI) algorithms in nonsmall cell lung cancer (NSCLC) prognostication. Studies were evaluated for the type of input data (histology and whether CT, PET, and MRI were used), cancer therapy intervention, prognosis performance, and comparisons to clinical prognosis systems such as TNM staging. Further comparisons were drawn between different types of AI, such as machine learning (ML) and deep learning (DL). Syntheses of therapeutic interventions and algorithm input modalities were performed for comparison purposes. The review adheres to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). The initial database identified 3880 results, which were reduced to 513 after the automatic screening, and 309 after the exclusion criteria. The prognostic performance of AI for NSCLC has been investigated using histology and genetic data, and CT, PET, and MR imaging for surgery, immunotherapy, and radiation therapy patients with and without chemotherapy. Studies per therapy intervention were 13 for immunotherapy, 10 for radiotherapy, 14 for surgery, and 34 for other, multiple, or no specific therapy. The results of this systematic review demonstrate that AI-based prognostication methods consistently present higher prognostic performance for NSCLC, especially when directly compared with traditional prognostication techniques such as TNM staging. The use of DL outperforms ML-based prognostication techniques. DL-based prognostication demonstrates the potential for personalized precision cancer therapy as a supplementary decision-making tool. Before it is fully utilized in clinical practice, it is recommended that it be thoroughly validated through well-designed clinical trials.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concurrent Trastuzumab Deruxtecan and Radiation Therapy in HER2-positive and HER2-low Metastatic Breast Cancer: Assessing the Efficacy.","authors":"Jihane Bouziane, Pierre Loap, Sofiane Allali, Laurence Escalup, Jean-Yves Pierga, Youlia Kirova","doi":"10.1097/COC.0000000000001237","DOIUrl":"10.1097/COC.0000000000001237","url":null,"abstract":"<p><p>The combination in patients with HER2-positive and HER2-low metastatic breast cancer (MBC) of Concurrent Trastuzumab Deruxtecan (T-DXd) and Radiation Therapy (RT) is not enough studied. We conducted a retrospective study including patients treated between 11/2020 and 01/2024. Patients with HER2-positive and HER2-low MBC who received concurrent T-DXd and RT were identified. Data on patient demographics, treatment regimens, radiation doses, toxicity profiles, efficacy, and treatment discontinuations were collected. The toxicities were graded using CTCAE V5.0. Population of 33 patients with HER2-positive and HER2-low MBC who underwent concurrent T-DXd&RT, were studied. The median follow-up (FU) was 14 months. There were 39.4 partial remissions and 9.4 attained complete remission. In addition, 39.4% experienced stable disease, and 12.1% faced disease progression necessitating a change in therapy. Safety assessment revealed that acute toxicities were mainly associated with systemic treatment. Survival analysis showed 11 deaths (33.3%) during the FU period, with a median overall survival of 26 months and median progression-free survival of 12 months. The combination of T-DXd with RT in demonstrates promising efficacy with a manageable safety profile. Further studies are warranted to fully elucidate the potential synergistic effects of this treatment regimen and its impact on patient outcome.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144644086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast Cancer Patient Treatment Experience at a National Cancer Institute-Designated Cancer Center Before Formal Navigation Integration.","authors":"Kolton Kardokus, Kerry A Stark, Anh B Lam, Shearwood McClelland","doi":"10.1097/COC.0000000000001231","DOIUrl":"https://doi.org/10.1097/COC.0000000000001231","url":null,"abstract":"<p><strong>Objectives: </strong>Breast cancer accounted for over 1/3 of new US cancer diagnoses in 2024, remains the most commonly diagnosed cancer globally, and is the leading cause of cancer-related mortality among women. We evaluated breast cancer patient experience at a National Cancer Institute-designated cancer center to assess potential barriers to optimal care.</p><p><strong>Methods: </strong>Over a 10-month period (4/1/24 to 1/31/25), eligible breast cancer patients identified in clinic visits and who self-reported diagnoses were surveyed about their experience. Each survey included a \"Likelihood to Recommend\" (LTR) question, scored on a 5-point Likert scale, as a proxy for satisfaction. We examined surveys from 2 service lines: medical practice (clinic visits) and outpatient oncology (radiation/infusion). We extracted demographic data from the electronic medical record. Underrepresented minorities (URMs) were defined as African American, Native American, and/or Hispanic patients. Fisher's exact test assessed differences by race and ethnicity (P<0.05).</p><p><strong>Results: </strong>Of 15,153 patients (76.5% White, 9.9% Black, 7.6% Native American, and 94.3% non-Hispanic), 2,066 patients (13.6% response rate) completed the surveys. Response rates were significantly higher among White/non-Hispanic patients compared with URMs (P=0.0001). For outpatient oncology, patient experiences did not significantly differ by race or ethnicity. For medical practice, a trend toward significance was observed by ethnicity (P=0.07), but not by race.</p><p><strong>Conclusions: </strong>Our retrospective cohort study found significantly lower survey response rates among URMs, which could indicate barriers to sharing patient experiences. These findings establish a baseline for comparison and support future implementation of targeted navigation programs to improve patient experience and care delivery.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gastric Cancer Mortality in the United States: A Two-Decade Analysis of Trends and Disparities (1999-2020).","authors":"Muzamil Khan, Abu Huraira Bin Gulzar, Fatima Shahid, Belal Hamed Mohamed, Amar Lal, Shree Rath, Nouman Aziz, Waseem Nabi, Anees Cheema, Usama Ali, Adnan Bhat","doi":"10.1097/COC.0000000000001235","DOIUrl":"https://doi.org/10.1097/COC.0000000000001235","url":null,"abstract":"<p><strong>Objectives: </strong>Gastric cancer mortality has declined in recent decades, yet sociodemographic disparities remain. This study analyzed national trends in gastric cancer mortality among US adults, with stratification by demographic and geographic factors.</p><p><strong>Methods: </strong>We examined gastric cancer deaths (ICD-10 C16) in adults aged ≥25 years using CDC WONDER data from 1999 to 2020. Mortality trends were analyzed by age, sex, race/ethnicity, region, and urbanization using joinpoint regression to calculate annual and average annual percent changes (APC, AAPC).</p><p><strong>Results: </strong>From 1999 to 2020, there were 276,023 gastric cancer deaths. Mortality declined more in males (AAPC: -2.97 [95% CI: -3.15 to -2.79]) than females (-2.42 [-2.64 to -2.21]). The largest declines were among Asians (-3.83 [-4.08 to -3.56]) and Blacks (-3.25 [-3.49 to -3.02]), followed by Whites (-2.96 [-3.13 to -2.87]) and Hispanics (-2.31 [-2.58 to -2.06]). Metropolitan areas saw greater declines (-2.72 [-2.83 to -2.62]) than rural areas (-2.41 [-2.68 to -2.12]). By region, the Northeast showed the steepest decline (-3.16 [-3.34 to -2.99]), followed by the Midwest, South, and West. Notably, mortality increased among adults aged 25 to 34 years (AAPC: 0.38 [-1.24 to 2.70]) and 35 to 44 years (0.87 [0.12 to 1.73]).</p><p><strong>Conclusions: </strong>Gastric cancer mortality declined overall but with persistent disparities. Rising rates among younger adults and slower declines in rural and western regions warrant further investigation and targeted interventions.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.","authors":"Arman Arabshomali, Swarnali Goswami, Prajakta P Masurkar","doi":"10.1097/COC.0000000000001209","DOIUrl":"https://doi.org/10.1097/COC.0000000000001209","url":null,"abstract":"<p><strong>Objectives: </strong>Breast cancer remains the most prevalent cancer among women in the United States, with hormone receptor-positive (HR+) and HER2-negative subtypes comprising a significant proportion of cases. Despite advancements in treatment, resistance to endocrine therapies remains a substantial clinical challenge, especially in patients with mutations in the PIK3CA gene.</p><p><strong>Methods: </strong>A literature review was conducted to evaluate the safety and efficacy of inavolisib in breast cancer. Studies published through November 2024 were identified using PubMed, Google Scholar, and ClinicalTrials.gov. Phases I to III clinical trials in English were included. The review focused on safety outcomes (eg, serious adverse events) and efficacy outcomes (eg, progression-free survival), which were summarized narratively.</p><p><strong>Results: </strong>Inavolisib, a selective PI3Kα inhibitor, presents a promising option for patients with PIK3CA-mutated HR+HER2-negative advanced or metastatic breast cancer. In the INAVO120 trial, inavolisib combined with palbociclib and fulvestrant significantly extended progression-free survival (PFS) in patients with PIK3CA mutations. The median PFS was 15.0 months for the treatment arm compared with 7.3 months in the placebo group (hazard ratio: 0.43, P<0.001). The objective response rate (ORR) was 58.4% in the treatment arm, underscoring the drug's antitumor efficacy. Safety profiles revealed manageable adverse events, primarily hyperglycemia, neutropenia, and stomatitis. The incidence of these side effects was notable but manageable with appropriate supportive care. Inavolisib offers a new treatment for HR+HER2-negative advanced breast cancer, showing promising efficacy and safety. However, implementation challenges include high costs, insurance coverage issues, and limited access to required genetic testing through FoundationOne Liquid CDx assay, potentially creating barriers to equitable patient access.</p><p><strong>Conclusions: </strong>Inavolisib represents a significant advancement in the treatment of advanced HR+HER2-negative breast cancer, offering an effective option for patients with PIK3CA mutations. However, to fully realize its potential, health care systems must address challenges related to patient access, insurance coverage, and the availability of companion diagnostics. Further long-term studies will be essential to assess the enduring impact of this treatment on patient outcomes.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Cutaneous T-Cell Lymphoma Treatment: Unveiling Novel Therapeutic Avenues and Clinical Implications.","authors":"Zaheer Qureshi, Abdur Jamil, Fatima Hameed, Navkirat Kahlon","doi":"10.1097/COC.0000000000001230","DOIUrl":"https://doi.org/10.1097/COC.0000000000001230","url":null,"abstract":"<p><strong>Objectives: </strong>The non-Hodgkin lymphoma class known as cutaneous T-cell lymphomas (CTCLs) is uncommon and diverse, mainly affecting the skin. The prognosis is dismal, and despite recent breakthroughs, few treatment options are available for advanced-stage disease. This narrative review outlines the current state of care for CTCLs, emphasizing innovative immunotherapies, targeted medicines, combination approaches, and epigenetic modifiers.</p><p><strong>Methods: </strong>This paper was conducted to summarize the newer approaches to treating CTCL, with a literature search spanning PubMed, Science Direct, and Cochrane databases that identified articles reporting emerging treatments. Selected articles were categorized into sections to summarize pertinent results in a narrative report.</p><p><strong>Results: </strong>Extracorporeal photopheresis with mogamulizumab, a monoclonal antibody targeting CCR4, has shown promise in treating skin and blood involvement while maintaining a good safety record. Additional treatments that have been highlighted include the antibody-drug combination brentuximab vedotin, which targets CD30; checkpoint inhibitors like pembrolizumab and durvalumab; and new medicines, including CD47 inhibitor TTI-621, IL-2/IL-9/IL-15 signaling inhibitor BNZ-1, pegylated interferon alpha-2a, and anti-KIR3DL2 antibody IPH4102. Even though the early clinical trial results for these novel treatments have been positive, more extensive research is required to determine the safety and efficacy of the treatments.</p><p><strong>Conclusions: </strong>This review emphasizes the necessity for ongoing research and individualized treatment plans while highlighting the promise of these cutting-edge techniques to enhance outcomes for patients with advanced CTCL.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Postoperative Venous Thromboembolism in Patients With Gynecologic Malignancies: A Meta-analysis.","authors":"Tingting Zhang, Zhuoxia Chen, Haina Fu","doi":"10.1097/COC.0000000000001232","DOIUrl":"https://doi.org/10.1097/COC.0000000000001232","url":null,"abstract":"<p><p>To systematically evaluate the risk factors for postoperative complications of venous thromboembolism in patients with gynecologic malignancies. Cohort studies and case-control studies on the risk factors of postoperative venous thromboembolism in gynecologic malignancy patients were included in the search of China Knowledge, Wanfang, Wipro, China Biomedical Literature Database, PubMed, Cochrane Library, Embase, and Web of Science databases from inception to March 2025, and were analyzed. Studies. Data were statistically analyzed using RevMan 5.2 software. A total of 19 studies involving 123,329 patients with gynecologic malignancies were included. The analysis showed that advanced age (OR=3.08, 95% CI=2.85-3.32, P<0.00001), open surgery (OR=9.18, 95% CI=2.38-35.34, P=0.001), high surgical complexity (OR=9.97, 95% CI=5.80-17.15, P<0.00001), and surgical duration (OR=3.33, 95% CI=2.97-3.73, P<0.00001), high BMI (OR=4.77, 95% CI=3.47-6.57, P<0.00001), comorbidities (OR=21.02, 95% CI=8.72-50.70, P<0.00001), and prolonged bed rest in the postoperative period ( OR=25.16, 95% CI=10.32-61.32, P<0.00001), high intraoperative bleeding (OR=107.53, 95% CI=17.71-652.85, P<0.00001), and high D-dimer level (OR=5.55, 95% CI=3.27-9.43, P<0.00001), advanced tumor stage (OR=7.58, 95% CI=2.22-25.90, P=0.001), high tumor grade (OR=27.67, 95% CI=8.39-91.18, P<0.00001), and occurrence of lymph node metastasis (OR=31.21, 95% CI=9.54-102.15, P<0.00001) were all were risk factors for postoperative venous thrombosis in patients with gynecologic malignancies. Clinical staff should take into account the 12 risk factors identified in this study to actively identify gynecologic malignant tumor patients at high risk for venous thromboembolism after surgery and provide targeted measures to prevent or reduce the risk of postoperative DVT.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the Rate and Quality of Breast Cancer Treatment Following Initial Diagnosis.","authors":"Jared Gregston, Nancy Etzold, Natalie Stratemeier, Shearwood McClelland","doi":"10.1097/COC.0000000000001229","DOIUrl":"https://doi.org/10.1097/COC.0000000000001229","url":null,"abstract":"<p><strong>Objectives: </strong>Care guidelines recommend specific treatment pathways for early-stage breast cancer, but real-world adherence may vary due to institutional workflow and system-level limitations. This study examined rates of guideline-concordant care (GCC) at a single academic medical center over 5 years and evaluated differences by stage, patient demographics and time frame involving the COVID-19 pandemic.</p><p><strong>Methods: </strong>A retrospective review was performed of all women diagnosed with American Joint Committee on Cancer (AJCC) Stage 0-III breast cancer at a National Cancer Institute-designated cancer center between September 1, 2019, and September 1, 2024. GCC was defined according to National Comprehensive Cancer Network (NCCN) guidelines as mastectomy alone, lumpectomy with radiation, or lumpectomy alone in patients ≥70. Demographic and clinical data were extracted, and rates of GCC were assessed by stage, race, insurance type, and for variance during the COVID-19 pandemic.</p><p><strong>Results: </strong>Among 1455 patients diagnosed with stage 0-III breast cancer, 981 (67.4%) received some form of treatment, and 515 (35.4%) received GCC. Stage II patients had the lowest rate of GCC (28.7%). Rates of GCC remained stable before and after April 2020, though total diagnoses declined. Black patients had the highest rate of GCC (52.1%), while Asian/Pacific Islander patients had the lowest (21.9%). No clear relationship was observed between insurance type or ZIP code-based income and GCC receipt.</p><p><strong>Conclusions: </strong>Most patients diagnosed with breast cancer received treatment, but fewer than half met criteria for GCC. Differences in GCC rate by stage and race suggest both institutional and patient-level barriers to standard care. System improvements aimed at strengthening coordination between diagnosis and treatment may help increase adherence to guideline-based breast cancer care.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Support Group Impressions of Hispanic-American Cancer Patients: Early Findings From the Navigator-Assisted Hypofractionation (NAVAH) Program.","authors":"Maria A Lasprilla-Pallares, Carmen C Soriano, Abizairie Sanchez-Feliciano, Carla Ponce, Shearwood McClelland","doi":"10.1097/COC.0000000000001226","DOIUrl":"https://doi.org/10.1097/COC.0000000000001226","url":null,"abstract":"<p><strong>Objectives: </strong>The Hispanic-American population is the nation's second-largest racial/ethnic group and the second most rapidly growing population. Radiation therapy (RT) is an indispensable, highly effective treatment for cancer; therefore, any barriers impairing RT access may yield deleterious consequences for Hispanic-Americans. The Navigator-Assisted Hypofractionation (NAVAH) program was developed to optimize RT access for all cancer patients. A key component of NAVAH is the use of culturally sensitive surveys to assess the impact of patient navigation before and after RT. We present initial findings from a Spanish-language cancer support group comprised of Hispanic-American patients as a baseline before implementation of NAVAH at our institution.</p><p><strong>Methods: </strong>A previously validated, Spanish-language, culturally sensitive survey was implemented to identify barriers to cancer care among Hispanic Americans. Participants were recruited to complete interviewer-administered surveys between monthly group visits. Surveys assessed several domains, including acceptability, accessibility, accommodation, affordability, and availability.</p><p><strong>Results: </strong>Eight cancer survivors completed surveys in person. Interviewees reported a positive but variable assessment of the availability, accommodation, and accessibility domains, suggesting that services may adequately meet patients' needs and preferences. However, responses in the acceptability domain reflected a strong perception of disparities and ethnic bias. In addition, feedback in the affordability domain indicates a heightened vulnerability to financial toxicity within this population.</p><p><strong>Conclusions: </strong>These initial findings from the NAVAH program underscore the persistent challenges faced by Hispanic-American cancer patients, particularly in the realms of perceived discrimination and financial toxicity. These insights emphasize the necessity for culturally sensitive interventions, such as bilingual patient navigation programs, to address and mitigate the multifaceted barriers encountered by Hispanic-American patients. The NAVAH program's approach of incorporating culturally attuned surveys and support mechanisms represents a promising step toward optimizing equity in cancer treatment. Moreover, these early impressions pave the way for further investigation involving patients actively receiving RT.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144610253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overactive Bladder Symptoms in Cancer Patients Undergoing Chemotherapy.","authors":"Margaret Lotz, Sarah Keates, Danielle Carr, Nabila Noor, Veronica Demtchouk, David Zurakowski, Steven J Staffa, William Winkelman, Lisa Weissmann, Susan Pories, Eman Elkadry","doi":"10.1097/COC.0000000000001227","DOIUrl":"https://doi.org/10.1097/COC.0000000000001227","url":null,"abstract":"<p><strong>Objectives: </strong>To determine if chemotherapy contributes to the development of overactive bladder (OAB) in female cancer patients.</p><p><strong>Methods: </strong>A prospective, longitudinal study was conducted from 2017 to 2023 at Mount Auburn Hospital to assess the effects of chemotherapy on the development of OAB. Sixty-five female patients diagnosed with nonmetastatic breast cancer, lung cancer, or lymphoma were asked to complete 5 validated questionnaires regarding bladder symptoms just before starting chemotherapy and again at 6 weeks, 3 months, 6 months, and 12 months.</p><p><strong>Results: </strong>Fifty-eight patients completed the study. Overall, we detected no significant increase in OAB symptoms at any time point relative to baseline. However, an analysis of the data according to different chemotherapy regimens revealed that patients being treated with human epidermal growth factor receptor-2 (HER2) monoclonal antibodies, either trastuzumab alone or in combination with pertuzumab, had significantly higher scores on the questionnaires after the start of chemotherapy. When the HER2-treatment group was further subdivided, we found that patients receiving both monoclonal antibodies, trastuzumab, and pertuzumab, reported more significant urinary tract discomfort and changes in quality of life, particularly at the 6-month and 12-month time points.</p><p><strong>Conclusions: </strong>We conclude from our study that women receiving both trastuzumab and pertuzumab for HER2-positive breast cancer may experience an increase in OAB symptoms during the course of their treatment.</p>","PeriodicalId":50812,"journal":{"name":"American Journal of Clinical Oncology-Cancer Clinical Trials","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}